These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28616208)

  • 1. Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey.
    El-Damanawi R; Harris T; Sandford RN; Karet Frankl FE; Hiemstra TF
    Clin Kidney J; 2017 Jun; 10(3):305-309. PubMed ID: 28616208
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
    El-Damanawi R; Lee M; Harris T; Mader LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Burrows A; Woznowski P; Ben-Shlomo Y; Karet Frankl FE; Hiemstra TF
    BMJ Open; 2018 May; 8(5):e022859. PubMed ID: 29743334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
    Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
    Amro OW; Paulus JK; Noubary F; Perrone RD
    Am J Kidney Dis; 2016 Dec; 68(6):882-891. PubMed ID: 27663039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.
    El-Damanawi R; Lee M; Harris T; Cowley LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Karet Frankl FE; Hiemstra TF
    QJM; 2020 Apr; 113(4):258-265. PubMed ID: 31665476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
    Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT; Gansevoort R; Perrone R; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Gutman T; Howell M; Ju A; Manera KE; Teixeira-Pinto A; Hamiwka LA; Tong A
    Trials; 2017 Nov; 18(1):560. PubMed ID: 29169385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease.
    Amin S; Sangadi I; Allman-Farinelli M; Badve SV; Boudville N; Coolican H; Coulshed S; Foster S; Fernando M; Haloob I; Harris DCH; Hawley CM; Holt J; Howell M; Kumar K; Johnson DW; Lee VW; Mai J; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    Kidney Med; 2023 Sep; 5(9):100691. PubMed ID: 37602144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease.
    Rangan GK; Wong ATY; Munt A; Zhang JQJ; Saravanabavan S; Louw S; Allman-Farinelli M; Badve SV; Boudville N; Chan J; Coolican H; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Gregory AV; Haloob I; Hawley CM; Holt J; Howard K; Howell M; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Pascoe E; Peduto A; Rangan A; Roger SD; Sherfan J; Sud K; Torres VE; Vilayur E; Harris DCH
    NEJM Evid; 2022 Jan; 1(1):EVIDoa2100021. PubMed ID: 38319283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
    Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD
    Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case for water in the treatment of polycystic kidney disease.
    Torres VE; Bankir L; Grantham JJ
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1140-50. PubMed ID: 19443627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study.
    Sanon Aigbogun M; Oberdhan D; Doane MJ; Rooney J; Inyart BC; Pao CS; Denny AH
    Int J Nephrol Renovasc Dis; 2021; 14():105-115. PubMed ID: 33880055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Jeremiah Metzger Lecture. Polycystic kidney disease: old disease in a new context.
    Grantham JJ
    Trans Am Clin Climatol Assoc; 2002; 113():211-24; discussion 224-6. PubMed ID: 12053711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.